Vertex Pharmaceuticals Inc (VRTX)

NASDAQ


	Symbol		Exchange		Currency
	VRTX		NASDAQ		USD	Real-time
	VRTX		Mexico		MXN	Delayed
	1VRTX		Milan		EUR	Real-time
	VRTX		TradeGate		EUR	Delayed
	VRTX		Frankfurt		EUR	Delayed
	VRTX34		B3		BRL	Delayed
	VRTX		Vienna		EUR	Real-time

Currency in USD

Disclaimer

481.71

+5.56(+1.17%)

Closed12/10

After Hours

481.710.00(0.00%)

12/10

Fair Value

Day's Range

475.87

482.89

52 wk Range

341.90

510.64

VRTX Income Statement

Featured here, the Income Statement (earnings report) for Vertex Pharmaceuticals Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

4,162.8

6,205.7

7,574.4

8,930.7

9,869.2

Total Revenues Growth

+36.59%

+49.08%

+22.06%

+17.91%

+10.51%

Cost Of Revenues

2,302.3

2,381.2

2,842

3,607.6

4,425.1

Gross Profit

1,860.5

3,824.5

4,732.4

5,323.1

5,444.1

Gross Profit Growth

+52.3%

+105.56%

+23.74%

+12.48%

+2.27%

Gross Profit Margin %

44.69%

61.63%

62.48%

59.6%

55.16%

Other Operating Expenses, Total

658.5

770.5

840.1

944.7

1,136.6

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+18.09%	+17.01%	+9.03%	+12.45%	+20.31%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	658.5	770.5	840.1	944.7	1,136.6
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

1,202

3,054

3,892.3

4,378.4

4,307.5

Operating Income Growth

+81.03%

+154.08%

+27.45%

+12.49%

-1.62%

EBIT Margin %

28.87%

49.21%

51.39%

49.03%

43.65%

Net Interest Expenses

5.2

-36

-56.6

89.8

570.6

Net Interest Expenses Growth

+115.24%

-792.31%

-57.22%

+258.66%

+535.41%

Interest Expense, Total

-58.5

-58.2

-61.5

-54.8

-44.1

Interest And Investment Income

63.7

22.2

4.9

144.6

614.7

Other Non Operating Expenses, Total

-5.4

-15.3

-12.2

-15.7

-15.3

EBT, Excl. Unusual Items

1,201.8

3,002.7

3,823.5

4,452.5

4,862.8

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-4.5

-197.7

-1,110.2

-71

-475.5

EBT, Incl. Unusual Items

1,394.9

3,116.9

2,730.4

4,232.4

4,379.8

EBT, Incl. Unusual Items Growth

+132.39%

+123.45%

-12.4%

+55.01%

+3.48%

EBT, Incl. Unusual Items Margin

33.51%

50.23%

36.05%

47.39%

44.38%

Income Tax Expense

218.1

405.2

388.3

910.4

760.2

Net Income to Company

1,176.8

2,711.7

2,342.1

3,322

3,619.6

Minority Interest

-

-

-

-

-

Net Income

1,176.8

2,711.7

2,342.1

3,322

3,619.6

Net Income Growth

-43.88%

+130.43%

-13.63%

+41.84%

+8.96%

Net Income Margin %

28.27%

43.7%

30.92%

37.2%

36.68%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

1,176.8

2,711.7

2,342.1

3,322

3,619.6

Basic EPS - Continuing Operations

4.58

10.44

9.09

12.97

14.05

Basic EPS - Continuing Operations Growth

-44.39%

+127.68%

-12.93%

+42.72%

+8.28%

Diluted EPS - Continuing Operations

4.51

10.29

9.01

12.82

13.89

Diluted EPS - Continuing Operations Growth

-44.24%

+128.16%

-12.44%

+42.29%

+8.35%

Basic Weighted Average Shares Outstanding

256.7

259.8

257.7

256.1

257.7

Diluted Weighted Average Shares Outstanding

260.7

263.4

259.9

259.1

260.5

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

1,308.9

3,163.5

4,017.9

4,526.7

4,477

EBITDA Growth

+77.75%

+141.69%

+27.01%

+12.66%

-1.1%

EBITDA Margin %

31.44%

50.98%

53.05%

50.69%

45.36%

EBIT